Notch signaling in prostate cancer: A moving target

Prostate

Volumn 74, Issue 9, 2014, Pages 933-945

  Carvalho, Filipe L F ^a   Simons, Brian W ^a   Eberhart, Charles G ^a   Berman, David M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

active surveillance; Notch pathway; prostate cancer; targeted therapy; tumor progression

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; BIOLOGICAL MARKER; GAMMA SECRETASE INHIBITOR; HEY1 PROTEIN; JAGGED2 PROTEIN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HES 6; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CANCER TISSUE; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CELL RENEWAL; CLINICAL TRIAL (TOPIC); DEVELOPMENT; DNA SEQUENCE; DOWN REGULATION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HUMAN; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATE SIZE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMATIC MUTATION; UROGENITAL SINUS;

ACTIVE SURVEILLANCE; NOTCH PATHWAY; PROSTATE CANCER; TARGETED THERAPY; TUMOR PROGRESSION;

ANIMALS; CELL DIFFERENTIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84901196449     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22811     Document Type: Article

References (104)

1. Artavanis-Tsakonas S, Muskavitch MA,. Notch: The past, the present, and the future. Curr Top Dev Biol 2010; 92: 1-29.
2. Artavanis-Tsakonas S, Rand MD, Lake RJ,. Notch signaling: Cell fate control and signal integration in development. Science 1999; 284 (5415): 770-776.
3. Ohlstein B, Spradling A,. Multipotent Drosophila intestinal stem cells specify daughter cell fates by differential notch signaling. Science 2007; 315 (5814): 988-992.
4. Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J, MacDonald HR, Aguet M,. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999; 10 (5): 547-558.
5. Hori K, Sen A, Artavanis-Tsakonas S,. Notch signaling at a glance. J Cell Sci 2013; 126 (Pt 10): 2135-2140.
6. Falix FA, Aronson DC, Lamers WH, Gaemers IC,. Possible roles of DLK1 in the Notch pathway during development and disease. Biochim Biophys Acta 2012; 1822 (6): 988-995.
7. Jhas S, Ciura S, Belanger-Jasmin S, Dong Z, Llamosas E, Theriault FM, Joachim K, Tang Y, Liu L, Liu J, Stifani S,. Hes6 inhibits astrocyte differentiation and promotes neurogenesis through different mechanisms. J Neurosci 2006; 26 (43): 11061-11071.
8. Gaiano N, Fishell G,. The role of notch in promoting glial and neural stem cell fates. Annu Rev Neurosci 2002; 25: 471-490.
9. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J,. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66 (4): 649-661.
10. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J, Baltimore D,. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183 (5): 2283-2291.
11. Zhu YM, Zhao WL, Fu JF, Shi JY, Pan Q, Hu J, Gao XD, Chen B, Li JM, Xiong SM, Gu LJ, Tang JY, Liang H, Jiang H, Xue YQ, Shen ZX, Chen Z, Chen SJ,. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: Prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 2006; 12 (10): 3043-3049.
12. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC,. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306 (5694): 269-271.
13. Beachy PA, Karhadkar SS, Berman DM,. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004; 432 (7015): 324-331.
14. Taipale J, Beachy PA,. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411 (6835): 349-354.
15. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature 2001; 414 (6859): 105-111.
16. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474 (7353): 609-615.
17. Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih Ie M, Wang TL,. Notch3 gene amplification in ovarian cancer. Cancer Res 2006; 66 (12): 6312-6318.
18. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Kumar-Sinha C, Chinnaiyan AM,. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 2011; 17 (12): 1646-1651.
19. Liefke R, Oswald F, Alvarado C, Ferres-Marco D, Mittler G, Rodriguez P, Dominguez M, Borggrefe T,. Histone demethylase KDM5A is an integral part of the core Notch-RBP-J repressor complex. Genes Dev 2010; 24 (6): 590-601.
20. Yustein JT, Liu YC, Gao P, Jie C, Le A, Vuica-Ross M, Chng WJ, Eberhart CG, Bergsagel PL, Dang CV,. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc Natl Acad Sci USA 2010; 107 (8): 3534-3539.
21. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M,. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9 (5): 617-628.
22. Hu C, Dievart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P,. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol 2006; 168 (3): 973-990.
23. Dievart A, Beaulieu N, Jolicoeur P,. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 1999; 18 (44): 5973-5981.
24. Politi K, Feirt N, Kitajewski J,. Notch in mammary gland development and breast cancer. Semin Cancer Biol 2004; 14 (5): 341-347.
25. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE,. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005; 65 (18): 8530-8537.
26. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L,. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008; 68 (13): 5226-5235.
27. Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C,. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 2011; 105 (6): 796-806.
28. Piechocki MP, Yoo GH, Dibbley SK, Lonardo F,. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer Res 2007; 67 (14): 6825-6843.
29. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L,. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008; 27 (37): 5019-5032.
30. Liu S, Wicha MS,. Targeting breast cancer stem cells. J Clin Oncol 2010; 28 (25): 4006-4012.
31. Korkaya H, Paulson A, Iovino F, Wicha MS,. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27 (47): 6120-6130.
32. Korkaya H, Wicha MS,. HER2 and breast cancer stem cells: More than meets the eye. Cancer Res 2013; 73 (12): 3489-3493.
33. Harrison H, Farnie G, Brennan KR, Clarke RB,. Breast cancer stem cells: Something out of notching ? Cancer Res 2010; 70 (22): 8973-8976.
34. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L,. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010; 16 (12): 3141-3152.
35. Kellokumpu-Lehtinen P, Santti R, Pelliniemi LJ,. Correlation of early cytodifferentiation of the human fetal prostate and Leydig cells. Anat Rec 1980; 196 (3): 263-273.
36. Timms BG, Mohs TJ, Didio LJ,. Ductal budding and branching patterns in the developing prostate. J Urol 1994; 151 (5): 1427-1432.
37. Cunha GR,. The role of androgens in the epithelio-mesenchymal interactions involved in prostatic morphogenesis in embryonic mice. Anat Rec 1973; 175 (1): 87-96.
38. Wang Y, Hayward S, Cao M, Thayer K, Cunha G,. Cell differentiation lineage in the prostate. Differentiation 2001; 68 (4-5): 270-279.
39. Leong KG, Wang BE, Johnson L, Gao WQ,. Generation of a prostate from a single adult stem cell. Nature 2008; 456 (7223): 804-808.
40. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM,. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009; 461 (7263): 495-500.
41. Blackwood JK, Williamson SC, Greaves LC, Wilson L, Rigas AC, Sandher R, Pickard RS, Robson CN, Turnbull DM, Taylor RW, Heer R,. In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. J Pathol 2011; 225 (2): 181-188.
42. Gaisa NT, Graham TA, McDonald SA, Poulsom R, Heidenreich A, Jakse G, Knuechel R, Wright NA,. Clonal architecture of human prostatic epithelium in benign and malignant conditions. J Pathol 2011; 225 (2): 172-180.
43. Choi N, Zhang B, Zhang L, Ittmann M, Xin L,. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 2012; 21 (2): 253-265.
44. Ousset M, Van Keymeulen A, Bouvencourt G, Sharma N, Achouri Y, Simons BD, Blanpain C,. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat Cell Biol 2012; 14 (11): 1131-1138.
45. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ,. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 2001; 61 (19): 7291-7297.
46. Valdez JM, Zhang L, Su Q, Dakhova O, Zhang Y, Shahi P, Spencer DM, Creighton CJ, Ittmann MM, Xin L,. Notch and TGFbeta form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell 2012; 11 (5): 676-688.
47. Martinez HD, Hsiao JJ, Jasavala RJ, Hinkson IV, Eng JK, Wright ME,. Androgen-sensitive microsomal signaling networks coupled to the proliferation and differentiation of human prostate cancer cells. Genes Cancer 2011; 2 (10): 956-978.
48. Grishina IB, Kim SY, Ferrara C, Makarenkova HP, Walden PD,. BMP7 inhibits branching morphogenesis in the prostate gland and interferes with Notch signaling. Dev Biol 2005; 288 (2): 334-347.
49. Wang XD, Leow CC, Zha J, Tang Z, Modrusan Z, Radtke F, Aguet M, de Sauvage FJ, Gao WQ,. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol 2006; 290 (1): 66-80.
50. Wang XD, Shou J, Wong P, French DM, Gao WQ,. Notch1-expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement. J Biol Chem 2004; 279 (23): 24733-24744.
51. Ceder JA, Jansson L, Helczynski L, Abrahamsson PA,. Delta-like 1 (Dlk-1), a novel marker of prostate basal and candidate epithelial stem cells, is downregulated by notch signalling in intermediate/transit amplifying cells of the human prostate. Eur Urol 2008; 54 (6): 1344-1353.
52. Orr B, Grace OC, Vanpoucke G, Ashley GR, Thomson AA,. A role for notch signaling in stromal survival and differentiation during prostate development. Endocrinology 2009; 150 (1): 463-472.
53. Orr B, Grace OC, Brown P, Riddick AC, Stewart GD, Franco OE, Hayward SW, Thomson AA,. Reduction of pro-tumorigenic activity of human prostate cancer-associated fibroblasts using Dlk1 or SCUBE1. Dis Model Mech 2013; 6 (2): 530-536.
54. Shen MM, Abate-Shen C,. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev 2010; 24 (18): 1967-2000.
55. Sarker D, Reid AH, Yap TA, de Bono JS,. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15 (15): 4799-4805.
56. Batch JA, Williams DM, Davies HR, Brown BD, Evans BA, Hughes IA, Patterson MN,. Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome. Hum Mol Genet 1992; 1 (7): 497-503.
57. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD, Greenberg NM,. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 2001; 276 (14): 11204-11213.
58. Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL, Parker MG,. Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol 2005; 25 (4): 1425-1436.
59. Ghosh S, Lau H, Simons BW, Powell JD, Meyers DJ, De Marzo AM, Berman DM, Lotan TL,. PI3K/mTOR signaling regulates prostatic branching morphogenesis. Dev Biol 2011; 360 (2): 329-342.
60. Stiles B, Groszer M, Wang S, Jiao J,., Wu H,. PTENless means more. Dev Biol 2004; 273 (2): 175-184.
61. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA,. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999; 59 (11): 2551-2556.
62. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H,. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4 (3): 209-221.
63. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR,. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59 (17): 4291-4296.
64. Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE,. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem 2009; 107 (5): 992-1001.
65. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL,. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19 (5): 575-586.
66. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM,. PTEN protein loss by immunostaining: Analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011; 17 (20): 6563-6573.
67. Bin Hafeez B, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V, Mukhtar H,. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res 2009; 15 (2): 452-459.
68. Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y, Sarkar FH,. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer 2006; 119 (9): 2071-2077.
69. Drabick JJ, Schell TD,. Poking CD40 for cancer therapy, another example of the Goldilocks effect. Cancer Biol Ther 2010; 10 (10): 994-996.
70. Hager B, Bickenbach JR, Fleckman P,. Long-term culture of murine epidermal keratinocytes. J Invest Dermatol 1999; 112 (6): 971-976.
71. Dalrymple S, Antony L, Xu Y, Uzgare AR, Arnold JT, Savaugeot J, Sokoll LJ, De Marzo AM, Isaacs JT,. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 2005; 65 (20): 9269-9279.
72. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC,. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004; 64 (19): 6854-6857.
73. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC,. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28 (3): 555-565.
74. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT,. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27 (26): 4300-4305.
75. Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Penson DF, Smith JA Jr, Barocas DA,. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol 2011; 186 (6): 2221-2227.
76. Kvale R, Moller B, Wahlqvist R, Fossa SD, Berner A, Busch C, Kyrdalen AE, Svindland A, Viset T, Halvorsen OJ,. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: A population-based study. BJU Int 2009; 103 (12): 1647-1654.
77. Ross AE, Marchionni L, Vuica-Ross M, Cheadle C, Fan J, Berman DM, Schaeffer EM,. Gene expression pathways of high grade localized prostate cancer. Prostate 2011; 25: 1-11.
78. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS,. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006; 103 (29): 10991-10996.
79. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39 (1): 41-51.
80. Rasul S, Balasubramanian R, Filipovic A, Slade MJ, Yague E, Coombes RC,. Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer 2009; 100 (12): 1879-1888.
81. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, Dang TP,. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007; 67 (17): 8051-8057.
82. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H,. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435 (7044): 959-963.
83. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM,. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279 (13): 12876-12882.
84. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, Meijerink J, Aifantis I, Basso G, Cordon-Cardo C, Ai W, Ferrando A,. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15 (1): 50-58.
85. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, Randolph S, Smeal T,. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010; 9 (6): 1618-1628.
86. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, Ridgway J, Schahin-Reed D, Dow GJ, Shelton A, Stawicki S, Watts RJ, Zhang J, Choy R, Howard P, Kadyk L, Yan M, Zha J, Callahan CA, Hymowitz SG, Siebel CW,. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464 (7291): 1052-1057.
87. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G,. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444 (7122): 1032-1037.
88. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G, Yan M,. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444 (7122): 1083-1087.
89. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE,. Direct inhibition of the NOTCH transcription factor complex. Nature 2009; 462 (7270): 182-188.
90. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ,. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 2012; 30 (19): 2348-2353.
91. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P,. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012; 30 (19): 2307-2313.
92. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena Illert A, von Figura K, Saftig P,. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 2002; 11 (21): 2615-2624.
93. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R,. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398 (6727): 518-522.
94. Fryer CJ, White JB, Jones KA,. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 2004; 16 (4): 509-520.
95. Sethi N, Dai X, Winter CG, Kang Y,. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011; 19 (2): 192-205.
96. Xing F, Okuda H, Watabe M, Kobayashi A, Pai SK, Liu W, Pandey PR, Fukuda K, Hirota S, Sugai T, Wakabayshi G, Koeda K, Kashiwaba M, Suzuki K, Chiba T, Endo M, Mo YY, Watabe K,. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 2011; 30 (39): 4075-4086.
97. Gallahan D, Callahan R,. Mammary tumorigenesis in feral mice: Identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. J Virol 1987; 61 (1): 66-74.
98. Jhappan C, Stahle C, Wolff M, Merlino G, Pastan I,. An epidermal growth factor receptor promoter construct selectively expresses in the thymus and spleen of transgenic mice. Cell Immunol 1993; 149 (1): 99-106.
99. Raafat A, Bargo S, Anver MR, Callahan R,. Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh). Oncogene 2004; 23 (58): 9401-9407.
100. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, Roberts JR, Carbone DP,. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 2000; 92 (16): 1355-1357.
101. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, Miele L, Bocchetta M,. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene 2010; 29 (17): 2488-2498.
102. Sjolund J, Johansson M, Manna S, Norin C, Pietras A, Beckman S, Nilsson E, Ljungberg B, Axelson H,. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 2008; 118 (1): 217-228.
103. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN,. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333 (6046): 1154-1157.
104. Demehri S, Turkoz A, Kopan R,. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009; 16 (1): 55-66.